Baotou Dongbao Bio-Tech Co Ltd (300239) - Total Assets
Based on the latest financial reports, Baotou Dongbao Bio-Tech Co Ltd (300239) holds total assets worth CN¥2.57 Billion CNY (≈ $376.65 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Baotou Dongbao Bio-Tech Co Ltd (300239) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Baotou Dongbao Bio-Tech Co Ltd - Total Assets Trend (2008–2025)
This chart illustrates how Baotou Dongbao Bio-Tech Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore 300239 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Baotou Dongbao Bio-Tech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Baotou Dongbao Bio-Tech Co Ltd's total assets of CN¥2.57 Billion consist of 45.0% current assets and 55.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.9% |
| Accounts Receivable | CN¥180.62 Million | 7.1% |
| Inventory | CN¥401.37 Million | 15.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥135.79 Million | 5.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Baotou Dongbao Bio-Tech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Baotou Dongbao Bio-Tech Co Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Baotou Dongbao Bio-Tech Co Ltd's current assets represent 45.0% of total assets in 2025, an increase from 42.0% in 2008.
- Cash Position: Cash and equivalents constituted 18.9% of total assets in 2025, up from 2.5% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 3.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 15.7% of total assets.
Baotou Dongbao Bio-Tech Co Ltd Competitors by Total Assets
Key competitors of Baotou Dongbao Bio-Tech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Baotou Dongbao Bio-Tech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.81 | 4.49 | 3.18 |
| Quick Ratio | 3.05 | 3.11 | 2.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥898.40 Million | CN¥940.82 Million | CN¥519.08 Million |
Baotou Dongbao Bio-Tech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Baotou Dongbao Bio-Tech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | CN¥2.55 Billion |
| Market Capitalization | $475.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Baotou Dongbao Bio-Tech Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Baotou Dongbao Bio-Tech Co Ltd's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Baotou Dongbao Bio-Tech Co Ltd (2008–2025)
The table below shows the annual total assets of Baotou Dongbao Bio-Tech Co Ltd from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.55 Billion ≈ $373.10 Million |
-2.87% |
| 2024-12-31 | CN¥2.62 Billion ≈ $384.11 Million |
-4.27% |
| 2023-12-31 | CN¥2.74 Billion ≈ $401.24 Million |
+18.80% |
| 2022-12-31 | CN¥2.31 Billion ≈ $337.75 Million |
+9.27% |
| 2021-12-31 | CN¥2.11 Billion ≈ $309.09 Million |
+48.97% |
| 2020-12-31 | CN¥1.42 Billion ≈ $207.49 Million |
+7.88% |
| 2019-12-31 | CN¥1.31 Billion ≈ $192.33 Million |
+9.64% |
| 2018-12-31 | CN¥1.20 Billion ≈ $175.41 Million |
+23.39% |
| 2017-12-31 | CN¥971.54 Million ≈ $142.17 Million |
+16.61% |
| 2016-12-31 | CN¥833.13 Million ≈ $121.91 Million |
+6.81% |
| 2015-12-31 | CN¥780.04 Million ≈ $114.14 Million |
+47.02% |
| 2014-12-31 | CN¥530.57 Million ≈ $77.64 Million |
+2.11% |
| 2013-12-31 | CN¥519.63 Million ≈ $76.04 Million |
+7.08% |
| 2012-12-31 | CN¥485.26 Million ≈ $71.01 Million |
+28.50% |
| 2011-12-31 | CN¥377.62 Million ≈ $55.26 Million |
+71.60% |
| 2010-12-31 | CN¥220.06 Million ≈ $32.20 Million |
+6.18% |
| 2009-12-31 | CN¥207.25 Million ≈ $30.33 Million |
+3.57% |
| 2008-12-31 | CN¥200.11 Million ≈ $29.28 Million |
-- |
About Baotou Dongbao Bio-Tech Co Ltd
Baotou Dongbao Bio-Tech Co.,Ltd engages in the design, research and development, production, and sale of gelatin and collagen and their derivative products in the People's Republic of China and internationally. It offers pharmaceutical gelation, food additives gelatin, and photographic gelatin; hydrolyzed collagen, collagen peptide, fish collagen peptide, and agglomerated collagen; and private la… Read more